Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2 · ActiveModality: small molecule (oral, once-daily)
Aliases EDP-938
Target RSV N-protein
Indications
Respiratory syncytial virus (RSV) in high-risk adults(Phase 2)
RSV in pediatric patients (28 days to 36 months)(Phase 2)
Catalysts
— Q4 2026
— 2027
— 2027
Status note Lead program. FDA Fast Track for RSV. Positive Phase 2b topline in high-risk adults (Sep 2025) and Phase 2 in pediatrics (Dec 2024). RESOLVE and LOTUS (first participant dosed Q3 2026) are the named next trials; company is exploring business development for RSV programs.
EDP-323
Phase 2 · ActiveModality: small molecule (oral, once-daily)
Target RSV L-protein
Indications
Respiratory syncytial virus (RSV)(Phase 2)
Status note FDA Fast Track for RSV. Positive Phase 2a challenge study topline (Sep 2024), including post-exposure prophylaxis signal. No next trial details stated; development focus is on zelicapavir.
EDP-978
Phase 1 · ActiveModality: small molecule (oral, once-daily)
Target KIT
Indications
Chronic spontaneous urticaria (CSU)(Phase 1)
Catalysts
— Q4 2026
Status note Clinical immunology candidate targeting mast cell depletion; Phase 1 in healthy volunteers dosed first participant April 2026; potential expansion to other mast cell-associated indications.
EPS-3903
Preclinical · ActiveModality: small molecule (oral)
Target STAT6
Indications
Atopic dermatitis (AD)(Preclinical)
Catalysts
— 2H 2026
Status note Preclinical lead candidate in STAT6 inhibitor program; initial proof-of-concept planned in AD, then other indications where IL-4/IL-13 pathway blockade applies. IND-enabling/scale-up ongoing.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.